Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $27.71 Consensus Target Price from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $27.71.

CNTA has been the topic of a number of recent research reports. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating for the company. Finally, Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock.

Centessa Pharmaceuticals Stock Up 2.7 %

CNTA traded up $0.30 on Monday, hitting $11.57. The company had a trading volume of 635,858 shares, compared to its average volume of 595,614. The stock has a fifty day simple moving average of $15.42 and a 200-day simple moving average of $16.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $1.54 billion, a P/E ratio of -7.56 and a beta of 1.53. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09.

Remove Ads

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. As a group, equities analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company's stock, valued at approximately $3,863,370.19. This trade represents a 3.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the transaction, the general counsel now owns 118,265 shares of the company's stock, valued at $1,808,271.85. This represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 260,168 shares of company stock worth $4,309,568. Corporate insiders own 11.59% of the company's stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in shares of Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after acquiring an additional 129,300 shares during the last quarter. Walleye Capital LLC bought a new position in Centessa Pharmaceuticals during the third quarter valued at approximately $187,000. Janus Henderson Group PLC purchased a new stake in Centessa Pharmaceuticals in the third quarter worth approximately $20,698,000. State Street Corp bought a new stake in Centessa Pharmaceuticals in the 3rd quarter worth approximately $777,000. Finally, Wellington Management Group LLP purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at $1,609,000. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.